Newly installed Health and Human Services Secretary Robert F.

The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot.

A federally funded study has found a possible link between aluminum in some childhood vaccines and persistent asthma, but experts say the study has several shortcomings.

A new government report shows Pfizer’s COVID-19 vaccine gave children 5 and older strong protection against hospitalization and death even during the omicron surge.

The omicron-fueled surge that is sending COVID-19 cases rocketing in the U.S. is putting children in the hospital in record numbers.

Taking the recommended COVID-19 vaccine doses may no longer be enough to be considered “fully vaccinated” in the future. The CDC is considering updating its definition to include a booster shot.

A panel of U.S. health advisers has endorsed booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine.

President Joe Biden’s administration drew up a strategy to contain one coronavirus strain, then another showed up that’s much more contagious.

The world’s leading COVID-19 vaccines may offer lasting protection that diminishes the need for frequent booster shots.

FILE - This September 2020, file photo provided by Johnson & Johnson shows a pharmacist preparing to give an experimental COVID-19 vaccine. (Johnson & Johnson via AP, File)WASHINGTON – U.S. health advisers endorsed a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic. One challenge in rolling out the new vaccine will be explaining how protective the J&J shot is after the astounding success of the first U.S. vaccines. One dose of the J&J vaccine was 85% protective against the most severe COVID-19. On Sunday, a CDC panel is expected to meet to recommend how to best prioritize use of the J&J vaccine.

The challenge will be explaining how protective the J&J shot is after the astounding success of the first U.S. vaccines. One dose of the J&J vaccine was 85% protective against the most severe COVID-19. For example, it’s a logical choice for homeless shelters where people may have moved on before their second dose of the Pfizer or Moderna vaccine. AdIn the U.S., health officials say it's critical for the government to send a clear message. “Right now, it’s not vaccine against vaccine, it’s vaccine against virus,” said Dr. Nirav Shah, director of the Maine Center for Disease Control and Prevention.

This July 2020 photo provided by Johnson & Johnson shows a vial of the COVID-19 vaccine in Belgium. (Johnson & Johnson via AP)WASHINGTON – U.S. health advisers endorsed a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic. One challenge in rolling out the new vaccine will be explaining how protective the J&J shot is after the astounding success of the first U.S. vaccines. One dose of the J&J vaccine was 85% protective against the most severe COVID-19. On Sunday, a CDC panel is expected to meet to recommend how to best prioritize use of the J&J vaccine.

FILE - This Dec. 2, 2020 photo provided by Johnson & Johnson shows vials of the Janssen COVID-19 vaccine in the United States. “I was reassured” that despite different variants, the J&J shot still protected against serious illness, said Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief. Across all countries, the analysis of the J&J vaccine showed protection began to emerge about 14 days after vaccination. Like other COVID-19 vaccines, the main side effects of the J&J shot are pain at the injection site and flu-like fever, fatigue and headache. AdIf the FDA clears the J&J shot for U.S. use, it will not boost vaccine supplies significantly right away.

The U.S. is considering a second vaccine, made by Moderna Inc., that could roll out in another week. Friday, Sanofi and GSK announced a months-long delay after early tests showed their vaccine didn’t work well enough in older adults. About 3 million doses of the Pfizer-BioNTech vaccine are expected in the first shipments around the country, according to officials with Operation Warp Speed, the Trump administration’s vaccine development program. Expected to follow health workers and nursing homes are other essential workers, older adults and people at high risk because of other health problems. If emergency use of Moderna’s vaccine also is authorized, the U.S. expects to vaccinate 20 million people by the end of December.

Trucks will roll out Sunday morning as shipping companies UPS and FedEx begin delivering Pfizer’s vaccine to nearly 150 distribution centers across the states, said Army Gen. Gustave Perna of Operation Warp Speed, the Trump administration’s vaccine development program. Initially, about 3 million doses were expected to be shipped nationwide. Perna compared the vaccine distribution effort to D-Day, the U.S.-led military offensive that turned the tide in World War II. The vaccine was timed to arrive Monday so health workers could receive the shots and begin giving them, Perna said. The announcement came after revelations that the White House opted not to lock in an additional 100 million doses of Pfizer’s vaccine for delivery in the second quarter of 2021.

Documents created by Pfizer for the meeting with the Food and Drug Administration advisory panel, as Pfizer seeks approval for emergency use of their COVID-19 vaccine, are seen on Thursday, Dec. 10, 2020. Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. Next week, the FDA will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

Pfizer announced Wednesday, Nov. 18, 2020, more results in its ongoing coronavirus vaccine study that suggest the shots are 95% effective a month after the first dose. The companies also have begun “rolling submissions” for the vaccine with regulators in Europe, the U.K. and Canada and soon will add this new data. Pfizer and BioNTech had initially estimated the vaccine was more than 90% effective after counting a group of the earliest infections that occurred in its final-stage testing. Pfizer would handle shipping of its own doses; the warp speed program will help with support and distributing additional companies' vaccines if and when they become available. Pfizer and BioNTech said they expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses in 2021.

University of Hong Kong scientists claim to have the first evidence of someone being reinfected with the virus that causes COVID-19. The man had mild symptoms the first time and none the second time; his more recent infection was detected through screening and testing at the Hong Kong airport. It shows that some people do not have lifelong immunity to the virus if they've already had it, To said. If there is a reinfection, it suggests the possibility there was residual immunity ... that helped protect the patient from getting sick again, Goodman said. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education.